BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 26763254)

  • 21. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
    Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
    Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic analysis of metastatic cutaneous squamous cell carcinoma.
    Li YY; Hanna GJ; Laga AC; Haddad RI; Lorch JH; Hammerman PS
    Clin Cancer Res; 2015 Mar; 21(6):1447-56. PubMed ID: 25589618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
    Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
    Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
    Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
    Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
    De Carvalho TG; De Carvalho AC; Maia DC; Ogawa JK; Carvalho AL; Vettore AL
    Oncol Rep; 2013 Jul; 30(1):334-40. PubMed ID: 23670291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
    Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
    Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
    Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.
    Sablin MP; Dubot C; Klijanienko J; Vacher S; Ouafi L; Chemlali W; Caly M; Sastre-Garau X; Lappartient E; Mariani O; Rodriguez J; Jouffroy T; Girod A; Calugaru V; Hoffmann C; Lidereau R; Berger F; Kamal M; Bieche I; Le Tourneau C
    Oncotarget; 2016 Jul; 7(30):47418-47430. PubMed ID: 27329726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
    Wayhelova M; Mikulasova A; Smetana J; Vallova V; Blazkova D; Filkova H; Moukova L; Kuglik P
    Neoplasma; 2016; 63(5):779-88. PubMed ID: 27468883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
    Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
    Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
    Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.
    Hunt JL; Barnes L; Lewis JS; Mahfouz ME; Slootweg PJ; Thompson LD; Cardesa A; Devaney KO; Gnepp DR; Westra WH; Rodrigo JP; Woolgar JA; Rinaldo A; Triantafyllou A; Takes RP; Ferlito A
    Eur Arch Otorhinolaryngol; 2014 Feb; 271(2):211-23. PubMed ID: 23467835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
    Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
    Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.